1,195 results on '"Oudard, S."'
Search Results
2. Circulating Biomarkers in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus in the Pre-nephrectomy Setting
3. Relationship between kalemia and intensive care unit admission or death in hospitalized COVID-19 patients: A cohort study
4. Nivolumab immunotherapy rechallenge for progressive laryngeal squamous cell carcinoma after failure of conventional treatment: A CARE case report.
5. Administration of neoadjuvant chemotherapy for muscle-invasive bladder cancer in real life: Are urologists still too cautious?
6. An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer
7. Rechallenge de l’immunothérapie par nivolumab pour un cancer épidermoïde du larynx en poursuite évolutive après échec des modalités conventionnelles de traitement : cas clinique CARE
8. Bone health in cancer: ESMO Clinical Practice Guidelines
9. HORM-OS : un parcours de soins pour améliorer le dépistage de l’ostéoporose chez les patients avec un cancer de prostate initiant une hormonothérapie
10. OA15.05 Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC
11. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab
12. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
13. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial
14. POS0502 IMPLEMENTATION OF A CLINICAL CARE PATHWAY FOR SYSTEMATIC BONE FRAGILITY ASSESSMENT AT THE INITIATION OF ANDROGEN DEPRIVATION IN PROSTATE CANCER PATIENTS (HORMOS PROJECT)
15. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
16. Controversies and consensus in the innovation access for cancer therapy in the European countries: on the subject of metastatic prostate cancer
17. INDOCYANINE GREEN FOR SENTINEL LYMPH NODE DETECTION IN EARLY BREAST CANCER: PROSPECTIVE EVALUATION OF DETECTION RATE AND TOXICITY: EP222
18. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders
19. PRAISE : décrire les effets immunologiques secondaires à l’immunothérapie dans le cancer – analyse de la qualité de vie
20. Résultats intermédiaires sur les 658 premiers patients de l’étude PRAISE (Patient-Reported AutoImmunity SEcondary to cancer immunotherapy) : étude de cohorte prospective multicentrique pour le suivi des manifestations auto-immunes sous immunothérapie
21. Spécificités cliniques des tumeurs de vessie n’infiltrant pas le muscle métastatique d’emblée : étude observationnelle multicentrique merinos
22. IMvigor010: Updated analysis of Overall Survival (OS) by circulating tumour DNA (ctDNA) status in patients with post-operative Muscle-Invasive Urothelial Carcinoma (MIUC) treated with atezolizumab
23. 1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial
24. 1762P MERINOS: Metastatic non muscle invasive urothelial carcinoma - An observational study
25. 1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial
26. 544P Feasibility of two different first-line carboplatin plus paclitaxel regimens in elderly women with ovarian cancer: A retrospective study
27. 1422P Validation of the prognostic value of the early modeled longitudinal PSA kinetics (KELIM and KPROD) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with taxanes in FIRSTANA
28. 1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial
29. LBA69 Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study
30. Évaluation radiologique de la réponse au traitement : application aux cancers du rein métastatiques sous traitement anti-angiogénique
31. Radiological evaluation of response to treatment: Application to metastatic renal cancers receiving anti-angiogenic treatment
32. Cancer bronchique, la gestion des situations critiques
33. Brèves de l’AERIO: Androgen receptor splice variant 7 et efficacité des taxanes dans le cancer de la prostate résistant à la castration
34. mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response
35. Apalutamide compared with darolutamide for the treatment of non-metastatic castration resistant prostate cancer: efficacy and tolerability in a matching-adjusted indirect comparison
36. Непрямое сравнение эффективности и безопасности апалутамида и даролутамида для лечения неметастатического кастрационно-резистентного рака предстательной железы по результатам двух независимых исследований с поправкой на разницу между популяциями пациентов
37. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
38. POSC134 Cost-Effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer
39. Pneumopathies médicamenteuses aux inhibiteurs de mTOR : différences entre transplantés et patients porteurs d’une tumeur
40. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
41. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib
42. Cas cliniques de cancer du rein des JOUM 2010
43. Feasibility of an adapted schedule of carboplatin + paclitaxel in elderly women with Ovarian Cancer: a retrospective cohort
44. P09.05 Plasma CD27, a surrogate of intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cancer
45. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network
46. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib
47. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients
48. Le point sur l’utilisation d’estramustine dans le cancer de la prostate métastatique
49. 73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis
50. 634P Prognostic value of the modeled PSA kinetic parameter (KELIM) in prostate cancer patients with rising PSA after primary local therapy treated in a prospective phase III trial with ADT +/- docetaxel
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.